Changyong Yang
5PUBLICATIONS
21CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Oct 30, 2025
HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles.Yunan Tian, Jieqiong Zhang, Xing Sun
|Oct 01, 2025
SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors.Yani Peng, Changyong Yang, Liwei Dong
|Aug 26, 2025
SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile.Li-Min Wang, Changyong Yang, Xing Sun
|Mar 20, 2025
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity.Simeng Chen, Yuan Lin, Dan Li
|Oct 10, 2018
Preclinical pharmacokinetics of a novel anti-c-Met antibody-drug conjugate, SHR-A1403, in rodents and non-human primates.Changyong Yang, Xiaoping Zhao, Xing Sun
Pageof 1
